Healthcare / Drug Manufacturers - Specialty & GenericBSE
$70.90
-1.19 (-1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $108.9M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$984M
P/E
11.3x
↓EV/EBITDA
5.5x
↓ROE
9.5%
↑Gross Margin
43.3%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.3%
FCF CAGR
-27.2%
FCF margin
2.6%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.73B · net income $80.8M · FCF $44.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.73B | $1.73B | $1.68B | $1.61B | $1.36B |
| Net Income | $80.8M | $80.8M | $111.6M | $78.6M | $62.6M |
| EBITDA | $180.5M | $180.5M | $224.1M | $190.3M | $151.4M |
| EPS | 5.82 | 5.82 | 8.04 | 5.66 | 4.51 |
| Gross Margin | 43.3% | 43.3% | 47.0% | 46.1% | 45.6% |
| Operating Margin | 6.0% | 6.0% | 9.0% | 8.2% | 8.5% |
| Net Margin | 4.7% | 4.7% | 6.6% | 4.9% | 4.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.05 |
| Cash Flow | |||||
| Free Cash Flow | $44.6M | $44.6M | $108.9M | $116.4M | $115.8M |
| Returns | |||||
| ROE | 9.5% | 9.5% | 13.9% | 10.9% | 9.4% |
| Valuation | |||||
| P/E | 11.29 | 11.29 | 21.03 | 13.60 | 17.27 |
| EV/EBITDA | 5.45 | 5.45 | 10.46 | 5.58 | 7.27 |
| P/B | 1.16 | 1.16 | 2.92 | 1.48 | 1.63 |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | 4.4% | 17.8% | — |
| EPS Growth | -27.6% | -27.6% | 42.0% | 25.5% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.6%
EPS terminal req.
$6.29
Spread vs growth
-30.2%
5Y implied EPS CAGR
5.5%
EPS terminal req.
$7.61
Spread vs growth
-33.1%
10Y implied EPS CAGR
7.7%
EPS terminal req.
$12.26
Spread vs growth
-35.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.0%
Start / end P/E
13.0x → 12.3x
EPS bridge
8.04 → 5.82
Residual
+1.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.